Survodutide

Survodutide dosing, mechanism of action, side effects, and clinical evidence. Complete reference for healthcare professionals.

Weight LossSubcutaneous injection2.4-6mg weekly (investigational)

Overview

Survodutide is a dual glucagon receptor (GCGR) and GLP-1 receptor agonist being developed by Zealand Pharma/Boehringer Ingelheim for obesity and MASH.

Mechanism of Action

Dual agonism — GCGR + GLP-1 receptor activation
Weight loss — Up to 19% body weight reduction in trials
Liver health — Designed to target metabolic dysfunction-associated steatohepatitis (MASH)
Glucagon effects — Enhanced energy expenditure and fat oxidation

Status

Phase 2 completed. Phase 3 trials ongoing for obesity and MASH.

Last updated: 2026-03-27